The startup aims to develop a low-cost, high-throughput proteomics platform that combines biochemistry with computer science and information technology.
Backed by BARDA, Merck and Institute for Systems Biology are studying multiomic data to understand infection pathways and find biomarkers for symptom risk.
The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.
Backed by €19 million in EU funding, the initiative, called [email protected], will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
Investigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia.
The collaborators are each providing funding and samples, and plan to study about 100 patients with a subset of Castleman disease to identify biomarkers.
Institute for Systems Biology head Leroy Hood presented vignettes from last year's pilot project, laying the groundwork for more widespread wellness-focused work.
The study, funded last month by the NIH, will use SRM-MS to identify proteins from a subset of promising pathways that are associated with DKD patients' progression to end-stage disease.
